News
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced...
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
Total national coverage footprint for PENFS increases to over 120 million covered livesCARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation...
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will...
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
Conference call will be held today, Tuesday, August 11 at 9:00 am ETCARMEL, Ind., Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis Expands Payer Coverage with New Policies
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced...
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will...
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
Conference call will be held today, Tuesday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and...
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will...
NeurAxis Expands Payer Coverage with Four New Medical Policies
CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced...
NeurAxis, Inc. Announces Preferred Stock Dividend
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced...